As of Thursday close, Pfizer Inc.’s (NYSE:PFE) stock was down -$0.52, moving down -1.45 percent to $35.38. The average number of shares traded per day over the past five days has been 19,470,379 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.78 fall in that time frame. In the last twenty days, the average volume was 21,810,326, while in the previous 50 days, it was 23,922,785.
Since last month, PFE stock rose 0.08%. Shares of the company fell to $34.65 on 08/04/23, the lowest level in the past month. A 52-week high of $54.93 was reached on 01/06/23 after having rallying from a 52-week low of $34.65. Since the beginning of this year, PFE’s stock price has dropped by -30.95% or -$15.86, and marked a new high 2 times. However, the stock has declined by -35.59% since its 52-week high.
PFE stock investors should be aware that Pfizer Inc. (PFE) stock had its last reported insider trading activity 116 days ago on May 08. Gottlieb Scott, the Director of the company, purchased of 1,000 shares for $38.58 on May 08. It resulted in a $38,580 investment by the insider. Gottlieb Scott added 1,000 shares at an average price of $38.42 on May 05. The insider now owns 5,000 shares following the transaction. On Mar 17, 10% Owner PFIZER INC bought 1,811,594 shares at $2.76 apiece. The transaction was valued at $4,999,999.
Valuation Metrics
Right now, Pfizer Inc. (PFE) has a P/E ratio of about 9.43. The stock’s beta is 0.58. Besides these, the trailing price-to-sales (P/S) ratio of 2.55, the price-to-book (PB) ratio of 2.02, and the price-to-cash flow ratio of 18.62 may also be considered.
The latest dividend of $0.41 per share was paid out, remained unchanged from last year’s $0.41. On Friday December 9 2022, a $0.01 dividend increase was announced.
Financial Health
In the three months ended June 29, Pfizer Inc.’s quick ratio stood at 1.80, while its current ratio was 2.10, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.62, and the total debt-to-equity ratio was 0.66. On the profitability front, the trailing twelve-month gross margin is 68.80% percent. In the year ended June 29, EBITDA margin amounted to 42.47%, whereas operating margins totaled 29.90%. Based on annual data, PFE earned $65.99 billion in gross profit and brought in $100.33 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 25.30%. Return on equity (ROE) for the past 12 months was 22.10%.
In Pfizer Inc.’s quarter-end financial report for June 29, it reported total debt of $61.36 billion. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. PFE’s revenue fell -117.86% to $18.28 billion during the quarter, while net income inched up to $12.73 billion. While analysts expected Pfizer Inc. to report $0.57 quarterly earnings, the actual figure was $0.67 per share, beating the consensus estimate by 17.50%. During the quarter, the company generated $3.49 billion in EBITDA. The liabilities of Pfizer Inc. were 120.88 billion at the end of its most recent quarter ended June 29, and its total debt was $65.67 billion. The value of shareholders’ equity is $5.65 billion.
Technical Picture
This quick technical analysis looks at Pfizer Inc.’s (PFE) price momentum. With a historical volatility rate of 11.46%, the RSI 9-day stood at 34.58% on 31 August.
With respect to its five-day moving average, the current Pfizer Inc. price is down by -2.16% percent or -$0.78. At present, PFE shares trade +1.09% above its 20-day simple moving average and -15.22% percent below its 100-day simple moving average. However, the stock is currently trading approximately -9.05% below its SMA50 and -25.67% below its SMA200.
Stochastic coefficient K was 37.20% and Stochastic coefficient D was 48.05%, while ATR was 0.69. Given the Stochastic reading of 17.57% for the 14-day period, the RSI (14) reading has been calculated as 39.72%. As of today, the MACD Oscillator reading stands at -0.49, while the 14-day reading stands at -0.39.
Analyst Ratings
JP Morgan reiterated its a Neutral rating on Pfizer Inc. (NYSE: PFE) in a note to investors. The analysts firm has however raised their price target to $41, representing a possible 21.38% increase in the stock price. Pfizer Inc. (PFE) has been rated Overweight by analysts. According to 0 brokerage firms, PFE is a sell, and 16 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 2 analysts rate Pfizer Inc. stock as buy, with 9 recommending it as overweight.
With a median target price of $41.00, the current consensus forecast for the stock is $32.00 – $75.00. Based on these forecasts, analysts predict Pfizer Inc. (PFE) will achieve an average price target of $43.81.
